Clinical Trials : Lymphoma, T-Cell

Not yet recruiting

Study Name: Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients
Condition: Peripheral T-cell Lymphoma
Date: 2016-06-17
Interventions:

Drug: Chidamide In the lead-in

Terminated

Study Name: Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
Condition: Peripheral T-Cell Lymphoma
Date: 2013-04-24
Interventions: Drug: Brentuximab vedotin Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day

Completed

Study Name: Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Date: 2009-03-19
Interventions: Drug: PXD101 Belinostat (PXD101) 1000 mg/m²administered as a 30 minute IV infusion on days 1-5 of e

Completed

Study Name: GDP in Frontline Chemotherapy for Patients With PTCL-NOS
Condition: Lymphoma, T-Cell, Peripheral
Date: 2015-03-26
Interventions: Drug: GDP chemotherapy gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin

Completed

Study Name: Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Date: 2006-08-14
Interventions: Drug: Pralatrexate Injection Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week

Completed

Study Name: Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma
Condition: Peripheral T Cell Lymphoma
Date: 2016-10-21
Interventions: Drug: Chidamide Chidamide is given to the patients as described, and drug concentration is measured in p

Completed

Study Name: E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Date: 2011-07-18
Interventions: Biological: denileukin diftitox (E7777) E7777 will be administered by intravenous (IV) infusion for 5 da

Active, not recruiting

Study Name: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Condition: Peripheral T-cell Lymphoma
Date: 2010-04-23

Not yet recruiting

Study Name: Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma
Condition: Peripheral T Cell Lymphoma
Date: 2016-07-24
Interventions: Drug: Chidamide with ICE regimen Chidamide and ICE regimen, dosage described in arm description

Completed

Study Name: Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
Condition: Peripheral T Cell Lymphoma
Date: 2016-04-19
Interventions: Drug: Chidamide

Search for Clinical Trial Results

Lymphoma, T-Cell - 42 Studies Found

Status	Study
Not yet recruiting	Study Name: Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients Condition: Peripheral T-cell Lymphoma Date: 2016-06-17 Interventions: Drug: Chidamide In the lead-in
Terminated	Study Name: Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Condition: Peripheral T-Cell Lymphoma Date: 2013-04-24 Interventions: Drug: Brentuximab vedotin Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day
Completed	Study Name: Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Condition: Peripheral T-cell Lymphoma Date: 2009-03-19 Interventions: Drug: PXD101 Belinostat (PXD101) 1000 mg/m²administered as a 30 minute IV infusion on days 1-5 of e
Completed	Study Name: GDP in Frontline Chemotherapy for Patients With PTCL-NOS Condition: Lymphoma, T-Cell, Peripheral Date: 2015-03-26 Interventions: Drug: GDP chemotherapy gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin
Completed	Study Name: Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Condition: Peripheral T-cell Lymphoma Date: 2006-08-14 Interventions: Drug: Pralatrexate Injection Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week
Completed	Study Name: Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma Condition: Peripheral T Cell Lymphoma Date: 2016-10-21 Interventions: Drug: Chidamide Chidamide is given to the patients as described, and drug concentration is measured in p
Completed	Study Name: E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma Condition: Peripheral T-Cell Lymphoma Date: 2011-07-18 Interventions: Biological: denileukin diftitox (E7777) E7777 will be administered by intravenous (IV) infusion for 5 da
Active, not recruiting	Study Name: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry Condition: Peripheral T-cell Lymphoma Date: 2010-04-23
Not yet recruiting	Study Name: Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma Condition: Peripheral T Cell Lymphoma Date: 2016-07-24 Interventions: Drug: Chidamide with ICE regimen Chidamide and ICE regimen, dosage described in arm description
Completed	Study Name: Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma Condition: Peripheral T Cell Lymphoma Date: 2016-04-19 Interventions: Drug: Chidamide